An international group of investigators led by a scientist at Cedars-Sinai has identified a genetic mutation that protects people from Type 2 diabetes. And they say it makes for a good target for drug developers.
An investigator at Columbia University Medical Center with close ties to Tarrytown, NY-based Armgo Pharma has published new animal data to back up the promise of their clinical-stage diabetes drug Rycal.
Several companies are experimenting with long-term wearable insulin delivery systems that work via continuous subcutaneous infusion to help ease the administration of the medication, thereby making it easier for patients to remain compliant. One such system from startup CeQur recently reported data from a small pilot study.
Investigators at Indiana University School of Medicine have added some fresh preclinical evidence to suggest that the protein Sestrin 3 could one day play a role in treating or preventing Type 2 diabetes.
Just as Eli Lilly and Boehringer Ingelheim's new diabetes drug Jardiance hit store shelves in the U.S., cost-effectiveness watchdogs in the U.K. were considering whether to give it their blessing. The verdict as of Thursday morning? Nay.
Sales of Lipitor, the best-selling drug of all time, may be waning, but litigation over the cholesterol fighter is growing--a lot.
Insulin pumps do a better job of helping control glucose levels in people with Type 2 diabetes than multiple daily injections, according to results from a new study funded by medical device maker Medtronic.
After four years of sifting data, the FDA says it found "no clear evidence" that Daiichi Sankyo's blockbuster blood pressure drug increased the risk of heart attack. But the agency will require new safety-related data on Benicar's official label.
Scientists at Stony Brook Medicine in New York have discovered a compound that could block a protein involved in determining a person's predisposition to getting diabetes.
The FDA may not have been so keen on Boehringer Ingelheim and Eli Lilly's Type 2 diabetes drug Jardiance when it issued a complete response letter in March for problems at its future production site. That didn't stop its across-the-pond counterpart from green-lighting the drug Friday--and it won't keep it from cracking the blockbuster barrier, analysts say. But that doesn't mean getting there will be easy.